Colorectal cancer progression is potently reduced by a glucose-free, high-protein diet: comparison to anti-EGFR therapy

Background & Aims: To enable rapid proliferation, colorectal tumor cells up-regulate epidermal growth factor receptor (EGFR) signaling and perform high level of aerobic glycolysis, resulting in substantial lactate release into the tumor microenvironment and impaired anti-tumor immune responses....

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:bioRxiv
Hlavní autori: Skibbe, Kerstin, Ann-Kathrin Brethack, Suenderhauf, Annika, Ragab, Mohab, Raschdorf, Annika, Hicken, Maren, Schlichting, Heidi, Preira, Joyce, Brandt, Jennifer, Castven, Darko, Foeh, Bandik, Pagel, Rene, Marquardt, Jens U, Sina, Christian, Derer, Stefanie
Médium: Paper
Jazyk:English
Vydavateľské údaje: Cold Spring Harbor Cold Spring Harbor Laboratory Press 16.06.2021
Cold Spring Harbor Laboratory
Vydanie:2.1
Predmet:
ISSN:2692-8205, 2692-8205
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Background & Aims: To enable rapid proliferation, colorectal tumor cells up-regulate epidermal growth factor receptor (EGFR) signaling and perform high level of aerobic glycolysis, resulting in substantial lactate release into the tumor microenvironment and impaired anti-tumor immune responses. We hypothesized that an optimized nutritional intervention designed to reduce aerobic glycolysis of tumor cells may boost EGFR-directed antibody (Ab)-based therapy of pre-existing colitis-driven colorectal carcinoma (CRC). Methods: CRC development was induced by azoxymethane (AOM) and dextran sodium sulfate (DSS) administration to C57BL/6 mice. AOM/DSS treated mice were fed a glucose-free, high-protein diet (GFHPD) or an isoenergetic control diet (CD) in the presence or absence of i.p. injection of PBS, an irrelevant control mIgG2a or an anti-EGFR mIgG2a. Ex vivo, health status, tumor load, metabolism, colonic epithelial cell differentiation and immune cell infiltration were studied. Functional validation was performed in murine and human CRC cell lines MC-38 or HT29-MTX. Results: AOM/DSS treated mice on GFHPD displayed reduced systemic glycolysis, resulting in improved tumoral energy homeostasis and diminished tumor load. Comparable but not additive to an anti-EGFR-Ab therapy, GFHPD was accompanied by enhanced tumoral differentiation and decreased colonic PD-L1 and splenic PD-1 immune checkpoint expression, presumably promoting intestinal barrier function and improved anti-tumor immune responses. In vitro, glucose-free, high-amino acid culture conditions reduced proliferation but improved differentiation of CRC cells in combination with down-regulation of PD-L1 expression. Conclusion: We here found GFHPD to metabolically reprogram colorectal tumors towards balanced OXPHOS, thereby improving anti-tumor T-cell responses and reducing CRC progression with a similar efficacy as EGFR-directed antibody therapy. Competing Interest Statement The authors have declared no competing interest.
AbstractList Background & Aims: To enable rapid proliferation, colorectal tumor cells up-regulate epidermal growth factor receptor (EGFR) signaling and perform high level of aerobic glycolysis, resulting in substantial lactate release into the tumor microenvironment and impaired anti-tumor immune responses. We hypothesized that an optimized nutritional intervention designed to reduce aerobic glycolysis of tumor cells may boost EGFR-directed antibody (Ab)-based therapy of pre-existing colitis-driven colorectal carcinoma (CRC). Methods: CRC development was induced by azoxymethane (AOM) and dextran sodium sulfate (DSS) administration to C57BL/6 mice. AOM/DSS treated mice were fed a glucose-free, high-protein diet (GFHPD) or an isoenergetic control diet (CD) in the presence or absence of i.p. injection of PBS, an irrelevant control mIgG2a or an anti-EGFR mIgG2a. Ex vivo, health status, tumor load, metabolism, colonic epithelial cell differentiation and immune cell infiltration were studied. Functional validation was performed in murine and human CRC cell lines MC-38 or HT29-MTX. Results: AOM/DSS treated mice on GFHPD displayed reduced systemic glycolysis, resulting in improved tumoral energy homeostasis and diminished tumor load. Comparable but not additive to an anti-EGFR-Ab therapy, GFHPD was accompanied by enhanced tumoral differentiation and decreased colonic PD-L1 and splenic PD-1 immune checkpoint expression, presumably promoting intestinal barrier function and improved anti-tumor immune responses. In vitro, glucose-free, high-amino acid culture conditions reduced proliferation but improved differentiation of CRC cells in combination with down-regulation of PD-L1 expression. Conclusion: We here found GFHPD to metabolically reprogram colorectal tumors towards balanced OXPHOS, thereby improving anti-tumor T-cell responses and reducing CRC progression with a similar efficacy as EGFR-directed antibody therapy.
Background & Aims: To enable rapid proliferation, colorectal tumor cells up-regulate epidermal growth factor receptor (EGFR) signaling and perform high level of aerobic glycolysis, resulting in substantial lactate release into the tumor microenvironment and impaired anti-tumor immune responses. We hypothesized that an optimized nutritional intervention designed to reduce aerobic glycolysis of tumor cells may boost EGFR-directed antibody (Ab)-based therapy of pre-existing colitis-driven colorectal carcinoma (CRC). Methods: CRC development was induced by azoxymethane (AOM) and dextran sodium sulfate (DSS) administration to C57BL/6 mice. AOM/DSS treated mice were fed a glucose-free, high-protein diet (GFHPD) or an isoenergetic control diet (CD) in the presence or absence of i.p. injection of PBS, an irrelevant control mIgG2a or an anti-EGFR mIgG2a. Ex vivo, health status, tumor load, metabolism, colonic epithelial cell differentiation and immune cell infiltration were studied. Functional validation was performed in murine and human CRC cell lines MC-38 or HT29-MTX. Results: AOM/DSS treated mice on GFHPD displayed reduced systemic glycolysis, resulting in improved tumoral energy homeostasis and diminished tumor load. Comparable but not additive to an anti-EGFR-Ab therapy, GFHPD was accompanied by enhanced tumoral differentiation and decreased colonic PD-L1 and splenic PD-1 immune checkpoint expression, presumably promoting intestinal barrier function and improved anti-tumor immune responses. In vitro, glucose-free, high-amino acid culture conditions reduced proliferation but improved differentiation of CRC cells in combination with down-regulation of PD-L1 expression. Conclusion: We here found GFHPD to metabolically reprogram colorectal tumors towards balanced OXPHOS, thereby improving anti-tumor T-cell responses and reducing CRC progression with a similar efficacy as EGFR-directed antibody therapy. Competing Interest Statement The authors have declared no competing interest.
Author Ragab, Mohab
Schlichting, Heidi
Ann-Kathrin Brethack
Derer, Stefanie
Sina, Christian
Preira, Joyce
Pagel, Rene
Castven, Darko
Hicken, Maren
Marquardt, Jens U
Raschdorf, Annika
Suenderhauf, Annika
Skibbe, Kerstin
Brandt, Jennifer
Foeh, Bandik
Author_xml – sequence: 1
  givenname: Kerstin
  surname: Skibbe
  fullname: Skibbe, Kerstin
– sequence: 2
  fullname: Ann-Kathrin Brethack
– sequence: 3
  givenname: Annika
  surname: Suenderhauf
  fullname: Suenderhauf, Annika
– sequence: 4
  givenname: Mohab
  surname: Ragab
  fullname: Ragab, Mohab
– sequence: 5
  givenname: Annika
  surname: Raschdorf
  fullname: Raschdorf, Annika
– sequence: 6
  givenname: Maren
  surname: Hicken
  fullname: Hicken, Maren
– sequence: 7
  givenname: Heidi
  surname: Schlichting
  fullname: Schlichting, Heidi
– sequence: 8
  givenname: Joyce
  surname: Preira
  fullname: Preira, Joyce
– sequence: 9
  givenname: Jennifer
  surname: Brandt
  fullname: Brandt, Jennifer
– sequence: 10
  givenname: Darko
  surname: Castven
  fullname: Castven, Darko
– sequence: 11
  givenname: Bandik
  surname: Foeh
  fullname: Foeh, Bandik
– sequence: 12
  givenname: Rene
  surname: Pagel
  fullname: Pagel, Rene
– sequence: 13
  givenname: Jens
  surname: Marquardt
  middlename: U
  fullname: Marquardt, Jens U
– sequence: 14
  givenname: Christian
  surname: Sina
  fullname: Sina, Christian
– sequence: 15
  givenname: Stefanie
  surname: Derer
  fullname: Derer, Stefanie
BookMark eNpNULFOwzAUtFCRKKUfwGaJhYEUP8d2HDZUtQWpEhLqHjnJS-sqjYPtAv17gsrAdDfcne7umow61yEht8BmAAweOeMwY2oGciaETqW4IGOucp5ozuToH78i0xD2jDGeK0gzMSZfc9c6j1U0La1MV6GnvXdbjyFY11EbaO8idrE9UY_1scKalidq6LY9Vi5g0njEB7qz210y-CLajtYW4xOt3KE33oYhJDpqumiTxWr5TuMOvelPN-SyMW3A6R9OyGa52MxfkvXb6nX-vE5KYEIkWIPmaaMgq5Q0ZSO1wjzTWBqdQ11ijnnJuRY8MwA6U0an0HAjOIcaJE8n5P4cW1rnv-1n0Xt7MP5U_F5WMFWALM6XDdK7s3TY8XHEEIu9O_puKFdwKUAqzbhIfwAFu21m
ContentType Paper
Copyright 2021. Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the associated terms available at https://www.biorxiv.org/content/10.1101/2021.06.15.448354v2
2021, Posted by Cold Spring Harbor Laboratory
Copyright_xml – notice: 2021. Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the associated terms available at https://www.biorxiv.org/content/10.1101/2021.06.15.448354v2
– notice: 2021, Posted by Cold Spring Harbor Laboratory
DBID 8FE
8FH
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
HCIFZ
LK8
M7P
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
FX.
DOI 10.1101/2021.06.15.448354
DatabaseName ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central
ProQuest Central Student
SciTech Premium Collection
Biological Sciences
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
bioRxiv
DatabaseTitle Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Biological Science Collection
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
Biological Science Database
ProQuest SciTech Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Academic UKI Edition
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
DatabaseTitleList
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2692-8205
Edition 2.1
ExternalDocumentID 2021.06.15.448354v2
Genre Working Paper/Pre-Print
GroupedDBID 8FE
8FH
ABUWG
AFKRA
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
HCIFZ
LK8
M7P
NQS
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PROAC
RHI
FX.
ID FETCH-LOGICAL-b1044-ed1823f617c65abf586e978eba891dbe9e9b228427a11876a831f2a4221d1523
IEDL.DBID M7P
ISSN 2692-8205
IngestDate Tue Jan 07 18:58:34 EST 2025
Fri Jul 25 09:17:32 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
License The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b1044-ed1823f617c65abf586e978eba891dbe9e9b228427a11876a831f2a4221d1523
Notes SourceType-Working Papers-1
ObjectType-Working Paper/Pre-Print-1
content type line 50
Competing Interest Statement: The authors have declared no competing interest.
OpenAccessLink https://www.proquest.com/docview/2541568024?pq-origsite=%requestingapplication%
PQID 2541568024
PQPubID 2050091
ParticipantIDs biorxiv_primary_2021_06_15_448354
proquest_journals_2541568024
PublicationCentury 2000
PublicationDate 20210616
20210615
PublicationDateYYYYMMDD 2021-06-16
2021-06-15
PublicationDate_xml – month: 06
  year: 2021
  text: 20210616
  day: 16
PublicationDecade 2020
PublicationPlace Cold Spring Harbor
PublicationPlace_xml – name: Cold Spring Harbor
PublicationTitle bioRxiv
PublicationYear 2021
Publisher Cold Spring Harbor Laboratory Press
Cold Spring Harbor Laboratory
Publisher_xml – name: Cold Spring Harbor Laboratory Press
– name: Cold Spring Harbor Laboratory
SSID ssj0002961374
Score 1.625595
SecondaryResourceType preprint
Snippet Background & Aims: To enable rapid proliferation, colorectal tumor cells up-regulate epidermal growth factor receptor (EGFR) signaling and perform high level...
SourceID biorxiv
proquest
SourceType Open Access Repository
Aggregation Database
SubjectTerms Amino acids
Antibodies
Azoxymethane
Cancer Biology
Cell culture
Cell differentiation
Cell proliferation
Colitis
Colorectal carcinoma
Dextran
Down-regulation
Energy balance
Epidermal growth factor
Epidermal growth factor receptors
Epithelial cells
Glucose
Glycolysis
High protein diet
Homeostasis
Immune response
Immunotherapy
Lymphocytes T
Metastases
PD-L1 protein
Spleen
Tumor cells
Tumor microenvironment
Tumors
Title Colorectal cancer progression is potently reduced by a glucose-free, high-protein diet: comparison to anti-EGFR therapy
URI https://www.proquest.com/docview/2541568024
https://www.biorxiv.org/content/10.1101/2021.06.15.448354
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3BTtwwELWABYlTgYKgpciVesSwdjbeuBck0G7LgVWEONBTZMdjKRLaLNmUdv--M06AA1Iv3BJFiqIZe2beePIeY99SF6SDYRDjoJ0YSQkiM4RaaSLKaMAsGKLYxHg2y-7vTd433Jb9WOVzTIyB2tcl9cjPEcgg1MgwpVwsHgWpRtHpai-hsc4GxJKQxNG9_KXHogwmq0jErLTBja-GaX-wiQuRYL8k7k6ZniFGSUgQYMtVdfO3enoTmGO2mX5473fusEFuF9DssjWY77GtTm9y9ZH9ucILCnH2gZfk7obH-ayOm4NXS76osYZuH1a8IUpX8NytuOX9XLsIDcApJ4ZjEfkdqjn3FbTfefmiZsjbmqOzKjH5Mb3l3d9dq312N53cXf0UvfKCcAjPRgI8wo4kYHVT6tS6kGYaEG6Cs5mR3oEB4xQmNjW2JFeubZbIoOxIKemxIEgO2Ma8nsMh48GrLAxt5Ckc-RSc16UvxzZVZciMgyP2tbd5sejoNQrySzHUhUyLzi9H7PjZ1EW_w5bFq50__f_xZ7ZNb6TxLqmP2Ubb_IYvbLN8aqtlc8IGl5NZfnsSFw7e5dc3-a9_QzjK7w
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Nb9QwEB2VlgpO5VMUWjAS3DBdezdeB6nqoXRp1bJaoT30ZtnxWIpUbZZsaMmP4j8ydrLlgMStB26RIllK5mnGbzx-D-Bd5oJwOAh8HJTjIyGQ6zyy1jgRlSukKhiS2cR4OtWXl_lsA36t78LEscp1TkyJ2ldF7JEfEJEhqqGppBwtv_PoGhVPV9cWGh0szrG9Icq2Ojz7TPF9L-XkZH58yntXAe6Ieow4etpSDwNV7kJl1oVMKyQqhc7qXHiHOeZOUtKWYxutuJXVQxGkHUkpPBW7IS17D7ZoFyF1mhSc3bZ0ZE61Mek-S5VTnpGDrD9HJdzHLoOIUqEi-0iUaBj9B7ZdWdU_y-u_6kAqbpOd_-y3PIKtmV1i_Rg2cPEEtjs3zfYp3BzTQ0zg9ooVEcw1S9NnnfIIK1dsWRFDaK5aVkfBWvTMtcyyfmqfhxrxA4v6zTypV5QL5ktsPrHi1quRNRUjKJb85MvkG-vurrXPYH4Xn_ocNhfVAl8AC17qMLBJhXHkM3ReFb4Y20wWQecOd-FtH2Kz7MRDTISBGSgjMtPBYBf21pE1ff5YmT9hffnv12_gwen864W5OJuev4KHcfU4yCbUHmw29Q_ch_vFdVOu6tcJqwzMHYPgN1E4IUw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Colorectal+cancer+progression+is+potently+reduced+by+a+glucose-free%2C+high-protein+diet%3A+comparison+to+anti-EGFR+therapy&rft.jtitle=bioRxiv&rft.au=Skibbe%2C+Kerstin&rft.au=Ann-Kathrin+Brethack&rft.au=Suenderhauf%2C+Annika&rft.au=Ragab%2C+Mohab&rft.date=2021-06-16&rft.pub=Cold+Spring+Harbor+Laboratory+Press&rft.issn=2692-8205&rft.eissn=2692-8205&rft_id=info:doi/10.1101%2F2021.06.15.448354
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2692-8205&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2692-8205&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2692-8205&client=summon